13F-HR filed by Propel Bio Management, LLC
Propel Bio Management, LLC filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-11, with 20 holding rows worth $117,123,993.
- Accession
- 0000898432-26-000087
- Filer
- CIK 1969764
- Filed
- 2026-02-11
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 20 entries on the cover page, a total value of $117,123,993 stated on the cover page (in dollars after the unit check, H1), rows summing to $117,123,993 with VALUE read as dollars as filed, 13F file number 028-23914. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerSimplify Asset Management Inc.028-20937
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| PLAINS GP HLDGS L P | 72651A207 | LTD PARTNR INT A | 1,272,360 | $24,352,970 | dollars as filed | |
| ACHIEVE LIFE SCIENCES INC | 004468500 | COMMON STOCK | 3,786,425 | $18,818,532 | dollars as filed | |
| PHATHOM PHARMACEUTICALS INC | 71722W107 | COMMON STOCK | 740,918 | $12,291,830 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 282,531 | $8,792,365 | dollars as filed | |
| Milestone Pharmaceuticals Inc | 59935V107 | COM | 4,118,321 | $8,319,008 | dollars as filed | |
| KYVERNA THERAPEUTICS INC | 501976104 | COMMON STOCK | 666,666 | $6,266,660 | dollars as filed | |
| COMPASS PATHWAYS PLC | 20451W101 | SPONSORED ADS | 861,778 | $5,946,268 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 1,000,000 | $4,650,000 | dollars as filed | |
| DELCATH SYSTEMS INC | 24661P807 | COMMON STOCK | 438,509 | $4,428,941 | dollars as filed | |
| ABEONA THERAPEUTICS INC | 00289Y206 | COM NEW | 830,780 | $4,378,211 | dollars as filed | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 154,300 | $4,190,788 | dollars as filed | |
| NEKTAR THERAPEUTICS | 640268306 | COMMON STOCK | 82,822 | $3,501,714 | dollars as filed | |
| OCULIS HOLDING AG | H5870P102 | CMN | 172,839 | $3,451,595 | dollars as filed | |
| SAB BIOTHERAPEUTICS INC | 78397T202 | COMMON STOCK | 652,881 | $2,441,775 | dollars as filed | |
| REGENXBIO INC | 75901B107 | COM | 116,896 | $1,683,302 | dollars as filed | |
| LeonaBio Inc | 04746L203 | COM | 149,279 | $1,130,042 | dollars as filed | |
| LENZ THERAPEUTICS INC | 52635N103 | COM | 59,085 | $945,360 | dollars as filed | |
| AARDVARK THERAPEUTICS INC | 002942100 | COM | 46,408 | $609,105 | dollars as filed | |
| ZEVRA THERAPEUTICS INC COM NEW | 488445206 | Stock | 63,683 | $570,600 | dollars as filed | |
| KALARIS THERAPEUTICS INC | 482929106 | COM | 42,053 | $354,927 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000898432-26-000087 | this filing | 2026-02-11 | acceptance time not in the bulk data set |